Ikena Oncology, Inc. (IKNA)
Largest Insider Buys in Sector
IKNA Stock Price History Chart
IKNA Stock Performance
About Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor …
Insider Activity of Ikena Oncology, Inc.
Over the last 12 months, insiders at Ikena Oncology, Inc. have bought $0 and sold $0 worth of Ikena Oncology, Inc. stock.
On average, over the past 5 years, insiders at Ikena Oncology, Inc. have bought $8.94M and sold $797,472 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,419 shares for transaction amount of $86,884 was made by Bonita David P () on 2022‑06‑22.
List of Insider Buy and Sell Transactions, Ikena Oncology, Inc.
| 2022-06-22 | 23,419 0.0656% | $3.71 | $86,884 | +14.75% | ||||
| 2022-06-22 | 66,806 0.1792% | $3.55 | $237,161 | +14.75% | ||||
| 2022-01-11 | Sale | Chief Scientific Officer | 964 0.0026% | $12.00 | $11,568 | -63.56% | ||
| 2021-12-14 | Sale | director | 5,959 0.0217% | $14.00 | $83,426 | -63.59% | ||
| 2021-12-14 | Sale | 10 percent owner | 5,959 0.0217% | $14.00 | $83,426 | -63.59% | ||
| 2021-12-13 | Sale | director | 8,330 0.0307% | $14.64 | $121,951 | -64.74% | ||
| 2021-12-13 | Sale | 10 percent owner | 8,330 0.0307% | $14.64 | $121,951 | -64.74% | ||
| 2021-12-10 | Sale | director | 11,989 0.0457% | $15.03 | $180,195 | -64.33% | ||
| 2021-12-10 | Sale | 10 percent owner | 11,989 0.0457% | $15.03 | $180,195 | -64.33% | ||
| 2021-12-10 | Sale | Chief Scientific Officer | 1,000 0.0037% | $14.76 | $14,760 | -64.33% | ||
| 2021-03-30 | director | 423,400 6.8729% | $16.00 | $6.77M | -49.34% | |||
| 2021-03-30 | director | 423,400 6.8729% | $16.00 | $6.77M | -49.34% | |||
| 2021-03-30 | director | 125,000 2.0291% | $16.00 | $2M | -49.34% | |||
| 2021-03-30 | 10 percent owner | 125,000 2.0291% | $16.00 | $2M | -49.34% |
Insider Historical Profitability
| Bonita David P | 1936097 4.012% | $1.72 | 2 | 0 | <0.0001% | |
| OrbiMed Genesis GP LLC | 1912678 3.9634% | $1.72 | 1 | 0 | +14.75% | |
| ORBIMED ADVISORS LLC | director | 1845872 3.825% | $1.72 | 1 | 0 | <0.0001% |
| FORMELA JEAN FRANCOIS | director | 1241935 2.5735% | $1.72 | 1 | 3 | <0.0001% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 1241935 2.5735% | $1.72 | 1 | 3 | <0.0001% |
Institutional Investor Ownership
| Atlas Venture Life Science Advisors Llc | $7.13M | 10.4 | 5.02M | 0% | +$0 | 0.66 | |
| Bvf Inc Il | $6.77M | 9.88 | 4.77M | 0% | +$0 | 0.05 | |
| Blue Owl Capital Holdings Lp | $5.53M | 8.06 | 3.89M | +99.17% | +$2.75M | 0.46 | |
| OrbiMed | $5.03M | 7.33 | 3.54M | 0% | +$0 | 0.04 | |
| Omega Fund Management Llc | $3.19M | 4.66 | 2.25M | 0% | +$0 | 2.37 |